Fremanezumab Brand Name– AJOVY

What is Fremanezumab

Fremanezumab is an injectable calcitonin gene-related peptide (CGRP) receptor antagonist indicated for migraine prophylaxis in adults. In 3-month clinical trials of patients with episodic migraine, fremanezumab significantly reduced monthly migraine days in comparison to placebo; monthly migraine days were reduced by 3.7 days, 3.4 days, and 2.2 days for fremanezumab once monthly, once quarterly, and placebo, respectively, from a baseline of approximately 9 days/month for each group.

At month 3, fremanezumab-treated chronic migraine patients experienced significant reductions in monthly migraine days of at least moderate severity of 4.6 days for monthly and 4.3 days for quarterly dosing from baselines of approximately 13 days/month vs. placebo.

A 50% or greater reduction in monthly migraine days was achieved by 44.4% to 47.7% of episodic migraineurs and 37.6% to 40.8% of chronic migraineurs who were treated with fremanezumab compared to 27.9% of episodic migraineurs and 18.1% of chronic migraineurs given placebo


  • migraine prophylaxis

Side Effects

  1. alopecia
  2. antibody formation
  3. constipation
  4. erythema
  5. injection site reaction
  6. pruritus
  7. rash
  8. urticaria

Monitoring Parameters

  • laboratory monitoring not necessary


  • breast-feeding
  • pregnancy


There are no drug interactions associated with Fremanezumab products.